{
    "Trade/Device Name(s)": [
        "Human IgA liquid reagent kit for use on SPAPLUS",
        "Human IgA liquid reagent kit for use on SPAPLUS\u00ae"
    ],
    "Submitter Information": "The Binding Site Group Ltd",
    "510(k) Number": "K192116",
    "Predicate Device Reference 510(k) Number(s)": [
        "K103824"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CFN"
    ],
    "Summary Letter Date": "September 4, 2019",
    "Summary Letter Received Date": "August 6, 2019",
    "Submission Date": "June 30, 2019",
    "Regulation Number(s)": [
        "21 CFR 866.5510"
    ],
    "Regulation Name(s)": [
        "Immunoglobulins A, G, M, D, And E Immunological Test System"
    ],
    "Analyte Class(es)": [
        "immunology"
    ],
    "Analyte(s)": [
        "IgA"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Lithium heparin plasma",
        "EDTA plasma"
    ],
    "Specimen Container(s)": [
        "Lithium heparin tube",
        "EDTA tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Binding Site SPAPLUS turbidimetric analyser"
    ],
    "Method(s)/Technology(ies)": [
        "Quantitative immunoturbidimetry",
        "Turbidimetric assay"
    ],
    "Methodologies": [
        "Quantitative measurement",
        "Turbidimetric analysis"
    ],
    "Submission Type(s)": [
        "Kit",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Human IgA liquid reagent kit for quantitative in vitro determination of IgA using SPAPLUS turbidimetric analyser",
    "Indications for Use Summary": "For quantitative in vitro determination of human IgA in serum, lithium heparin or EDTA plasma; aids diagnosis of abnormal protein metabolism and susceptibility to infection, results to be used in conjunction with other clinical and laboratory findings",
    "fda_folder": "Immunology"
}